Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1099 - Negative Lymph Node Count is a Significant Prognostic Factor in Patient with Stage IV Gastric Cancer after Palliative Gastrectomy

Date

09 Sep 2017

Session

Poster display session

Topics

Surgical Oncology;  Radiation Oncology;  Gastric Cancer

Presenters

Changhua Zhuo

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

C. Zhuo, M. Ying, R. Lin, X. Wu, S. Guan, C. Yang

Author affiliations

  • Gastrointestinal Surgical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, 350014 - Fuzhou/CN
More

Resources

Abstract 1099

Background

Negative lymph node (NLN) count has been validated as a protective predictor in various cancers after radical resection. However, the prognostic value of NLN count in the setting of gastric cancer patients who have received palliative resection has not been investigated. The aim of the present study was to explore the effect of NLN counts on the survival outcomes in patients with stage IV gastric cancer after palliative resection.

Methods

Surveillance, Epidemiology, and End Results Program (SEER)-registered gastric cancer patients were used for analysis in this study. Kaplan-Meier survival curves and multivariate Cox proportional hazards model were used to assess the risk factors for survival.

Results

A total of 1,495 patients with stage IV gastric cancer underwent palliative resection were identified from SEER database between 2004 and 2011. It showed that NLN count (P < 0.001) and N stage (P 

Conclusions

Our present study revealed that NLN count was an independent prognostic predictor in stage IV gastric cancer after palliative resection. Standard lymph node dissection, such as D2 lymphadectomy maybe still necessary during palliative resection for patients with metastatic gastric cancer.

Clinical trial identification

N/A

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.